23 Jul, 2026
According to Straits Research, the global viral vector manufacturing market size was valued at $2.99 billion in 2025 and is projected to grow from $3.62 billion in 2026 to $16.73 billion by 2034, registering a CAGR of 21.08% during the forecast period 2026–2034.
Molecular biologists use viral vectors to introduce genetic material into cells. In order to treat genetic disorders, it is used to express and present pathogenic antigens to simulate an infection and elicit an immune response. Since it aids in treating numerous diseases, such as heart defects, metabolic diseases, and neurodegenerative disorders, it has numerous applications in life science research, gene therapy, and vaccination.
Increasing Prevalence of Cancers, Infectious Diseases, and Genetic Disorders Drives the Global Market
Cancer is most prevalent in clinical trials for gene therapy. Cancer gene therapy stops the vascularization of tumors, kills cancerous cells, and enhances the immune system's response to tumor antigens. Many acquired diseases are treated using gene and cell therapy. Viral vector production is anticipated to increase during the forecast period due to promising therapeutic results and increasing competition among leading biopharmaceutical companies to have gene therapy products approved and sold for unmet medical needs.
Favorable Government Initiatives Creates Tremendous Opportunities
Significant government initiatives are in place to advance precision and personalized medicine, bolstering the R&D efforts of businesses and academia. Direct funding from the government, increased public awareness, and changes to the regulatory environment, like accelerated approval processes, are all driving market expansion. Additionally, several companies combine, acquire, and publish products related to viral vectors. For instance, Merck revealed plans to support its Bio Reliance viral and gene therapy service by opening a second Carlsbad in the United States in April 2020.
Europe is the most significant shareholder in the global viral vector manufacturing market and is expected to grow at a CAGR of 28.37% during the forecast period. The German market for the production of viral vectors is growing due to increased R&D efforts and advantageous pharmaceutical regulations. The country also has a high rate of cancer cases and a large number of businesses involved in healthcare. The nation's major market players' recent innovations and developments in the technology used to create viral vectors have contributed to the market's growth.
North America is expected to grow at a CAGR of 26.84%, generating USD 2,232.74 million during the forecast period. The United States is anticipated to maintain a dominant position in the global viral vector manufacturing market throughout the entire forecast period as a result of the rising number of clinical studies, funding for viral vector development, the presence of significant market players, and the rising prevalence of genetic disorders, cancer, and infectious diseases. In addition, the Organization for Economic Co-operation and Development (OECD) estimated that US biotechnology companies spend 15% of their total budgets on research and development as of 2020.
sales@straitsresearch.com